ReviewJournal of Cancer2019
A long way to the battlefront: CAR T cell therapy against solid cancers.
Review in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer.Clinical and experimental medicine · 2025Review
- CX3CR1Cancer science · 2024Review
- Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.Medical oncology (Northwood, London, England) · 2024Review
- Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.Frontiers in molecular biosciences · 2024Review
- Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.Molecular therapy oncolytics · 2023Review
- CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies.iScience · 2023Article
- Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.Cancer research · 2023Article
- Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy.Advanced pharmaceutical bulletin · 2022Review
- The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?International journal of biological sciences · 2022Review
- Emerging Therapeutic Agents for Colorectal Cancer.Molecules (Basel, Switzerland) · 2021Review
- X-ray-Fluorescence Imaging for In Vivo Detection of Gold-Nanoparticle-Labeled Immune Cells: A GEANT4 Based Feasibility Study.Cancers · 2021Article
- Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.Frontiers in oncology · 2021Review
- CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety.Journal of Cancer · 2021Review
- Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire.Nature reviews. Clinical oncology · 2020Review
- Review
- Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.Acta bio-medica : Atenei Parmensis · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptors (CARs) are engineered synthetic receptors that redirect and reprogram T cells to tumor surface antigens for subsequent eradication. The unprecedented efficacy of CD19-CAR T cells against B-cell malignancies has inspired oncologists to extend these efforts for the treatment of solid tumors. However, limited success has been achieved so far, partially due to some of the formidable challenges, e.g. suppression of full activation, inhibition of T cell localization, lacking of ideal targets, inefficient trafficking and infiltration, immunosuppression of microenvironment, and the probability of off targets and associated side effects. Significant progresses have being made recently. Thus, an updated summary is urgently needed. Here in this review, we discuss the advantages and some of the key hurdles encountered by CAR T cell therapy in solid tumors as well as the strategies adopted to improve therapeutic outcomes of this approach. Continuing efforts to increase therapeutic potential and decrease the adverse effects of adaptive cell transfer are suggested as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.